NYSE New 52-Week Highs And Lows
Ardent Health to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Truist Financial Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Maintains Target Price $22
Truist Financial Sticks to Its Buy Rating for Ardent Health Partners, Inc. (ARDT)
Truist Financial Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Announces Target Price $22
Loop Capital Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Raises Target Price to $21
A Quick Look at Today's Ratings for Ardent Health Partners(ARDT.US), With a Forecast Between $21 to $27
Ardent Health Partners Is Maintained at Buy by Loop Capital
Truist Adjusts Ardent Health Partners' PT to $22 From $21, Keeps Buy Rating
Buy Rating Affirmed: Ardent Health Partners' Impressive Performance and Growth Potential
Express News | Ardent Health Partners Inc : Mizuho Raises Target Price to $21 From $20
Analysts Are Bullish on These Healthcare Stocks: Biote (BTMD), Ardent Health Partners, Inc. (ARDT)
Ardent Health Partners Price Target Maintained With a $24.00/Share by Stephens & Co.
Ardent Health Partners Analyst Ratings
Loop Capital Initiates Ardent Health Partners(ARDT.US) With Buy Rating, Announces Target Price $18
Truist Financial Maintains Ardent Health Partners(ARDT.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Encompass Health (EHC) and Ardent Health Partners, Inc. (ARDT)
Morgan Stanley Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Maintains Target Price $27
Ardent Health Partners, LLC GAAP EPS of $0.34, Revenue of $1.47B
Ardent Health Partners | 10-Q: Quarterly report
No Data